It is simply a case of "hey we should put this out to help keep the No Voters below 65%" IMHO.
The bit that bears noticing from the original announcement is...
Dr Andy Fischer, CEO Medgate added: “ResApp continues to be an exemplary partner and over the
course of the last 12 months we’ve built further evidence of the benefits of ResAppDx to our clinicians
and patients. We look forward to expanding our use of ResAppDx to further realise these benefits for
our patients. Our intention is to be the most innovative leader in the global telehealth market and the
adoption of ResApp’s AI plays an important role in helping us to achieve this by transforming the patient
journey".
Perhaps some more news is due soon on Medgate's intention to roll Dx out across India? One would think that if Medgate are contributing to RAP revenue at the moment then simply doing some pro rata sums would clearly estimate a figure that would reflect the expected new German (and Indian) usage revenue.
This all assumes that Medgate is paying for the use of ResAppDx and isn't on some sort of freebie just so RAP can get some actual use feedback that RAP can use to attract and market to other telehealth platforms.
Do we even know whether Medgate are paying for the use of Dx yet? Just asking...
It keeps getting weirder and weirder. Par for the course though. SP up 4% this morning...I hope that Pfizer got some sleep over the weekend. The RAP sleepy sleepy approval just may have shaken up the RAP scene in the USA somewhat...lets see!
- Forums
- ASX - By Stock
- RAP
- Ann: Medgate Licence Agreement Clarification Announcement
Ann: Medgate Licence Agreement Clarification Announcement, page-14
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)